Skip to main content
. 2020 Jan 24;135(16):1396–1405. doi: 10.1182/blood.2019003526

Figure 2.

Figure 2.

PFS and OS according to TMTV before R-CHOP and per maintenance treatment arms. (A) PFS for all patients, (B) OS for all patients, (C) PFS in patients receiving lenalidomide maintenance after R-CHOP, (D) PFS in patients receiving placebo after R-CHOP, (E) OS in patients receiving lenalidomide maintenance after R-CHOP, and (F) OS in patients receiving placebo after R-CHOP.